Cancer Focus Target early stage pipeline with strategic partnerships or licensing deals to accelerate development of novel cancer therapies, leveraging Myrexis focus on first-in-class or best-in-class candidates.

Clinical and Preclinical Position opportunities around co-development, funded research collaborations, or sponsored programs that align with their mixed clinical and preclinical portfolio to expand market access and de-risk late-stage development.

Mid-Sized Advantage Engage through scalable partnerships that fit a smaller company profile, offering flexible collaboration models, manufacturing support, and access to capital or CRO networks to accelerate timelines.

Tech Enablement Offer cloud, data analytics, and software tooling collaborations to optimize research workflows, regulatory submissions, and real-world data capture, aligning with their tech stack and digital maturity.

Funding Readiness Present co-funding, milestone-based financing, or grant-ready programs tied to pipeline milestones to enhance financial planning and attract larger strategic investors seeking diversifying oncology assets.